K
KimC
Hi, everyone.
June 14 is my sixteen-week follow-up cath at SHANDS for the WISE study. (See info below if you're curious about WISE). The adenosine provocation cath will reveal if the study med has improved blood flow in my heart.
My last coronary flow reserve was 2.6. (Normal CFR is 3.5-14.0). At that point in time, I was diagnosed with angina decubitus due to cardiac failure.
I'm happy to say that I no longer feel symptomatic unless I really overdo it or eat poorly. I've also adjusted emotionally but wonder if others handle the anxiety better than I do. (Feel free to add your advice. I'm thick-skinned).
Dr. Kerensky also plans to further investigate the myocardial bridge during the cath. The only "cure" for the kink is bypass. Many people with bridges never have to cross that bridge ... (awful joke).
Has anyone had or heard of bypass surgery and aortic valve replacement at the same time? I have no idea if it's even possible, or if they'd want to perform either.
I guess only time will tell.
I'm hoping that the medications will have improved things. I'll give y'all an update after the cath.
Thanks for listening.
Best,
Kim
P.S. Did I mention I'm scared *@%$less to have another adenosine cath?
---------------------------------------------------
Info on WISE study:
OBJECTIVES: The Women's Ischemia Syndrome Evaluation (WISE) is a National Heart, Lung and Blood Institute-sponsored, four-center study designed to: 1) optimize symptom evaluation and diagnostic testing for ischemic heart disease; 2) explore mechanisms for symptoms and myocardial ischemia in the absence of epicardial coronary artery stenoses, and 3) evaluate the influence of reproductive hormones on symptoms and diagnostic test response.
BACKGROUND: Accurate diagnosis of ischemic heart disease in women is a major challenge to physicians, and the role reproductive hormones play in this diagnostic uncertainty is unexplored. Moreover, the significance and pathophysiology of ischemia in the absence of significant epicardial coronary stenoses is unknown.
METHODS: The WISE common core data include demographic and clinical data, symptom and psychosocial variables, coronary angiographic and ventriculographic data, brachial artery reactivity testing, resting/ambulatory electrocardiographic monitoring and a variety of blood determinations. Site-specific complementary methods include physiologic and functional cardiovascular assessments of myocardial perfusion and metabolism, ventriculography, endothelial vascular function and coronary angiography. Women are followed for at least 1 year to assess clinical events and symptom status.
June 14 is my sixteen-week follow-up cath at SHANDS for the WISE study. (See info below if you're curious about WISE). The adenosine provocation cath will reveal if the study med has improved blood flow in my heart.
My last coronary flow reserve was 2.6. (Normal CFR is 3.5-14.0). At that point in time, I was diagnosed with angina decubitus due to cardiac failure.
I'm happy to say that I no longer feel symptomatic unless I really overdo it or eat poorly. I've also adjusted emotionally but wonder if others handle the anxiety better than I do. (Feel free to add your advice. I'm thick-skinned).
Dr. Kerensky also plans to further investigate the myocardial bridge during the cath. The only "cure" for the kink is bypass. Many people with bridges never have to cross that bridge ... (awful joke).
Has anyone had or heard of bypass surgery and aortic valve replacement at the same time? I have no idea if it's even possible, or if they'd want to perform either.
I guess only time will tell.
I'm hoping that the medications will have improved things. I'll give y'all an update after the cath.
Thanks for listening.
Best,
Kim
P.S. Did I mention I'm scared *@%$less to have another adenosine cath?
---------------------------------------------------
Info on WISE study:
OBJECTIVES: The Women's Ischemia Syndrome Evaluation (WISE) is a National Heart, Lung and Blood Institute-sponsored, four-center study designed to: 1) optimize symptom evaluation and diagnostic testing for ischemic heart disease; 2) explore mechanisms for symptoms and myocardial ischemia in the absence of epicardial coronary artery stenoses, and 3) evaluate the influence of reproductive hormones on symptoms and diagnostic test response.
BACKGROUND: Accurate diagnosis of ischemic heart disease in women is a major challenge to physicians, and the role reproductive hormones play in this diagnostic uncertainty is unexplored. Moreover, the significance and pathophysiology of ischemia in the absence of significant epicardial coronary stenoses is unknown.
METHODS: The WISE common core data include demographic and clinical data, symptom and psychosocial variables, coronary angiographic and ventriculographic data, brachial artery reactivity testing, resting/ambulatory electrocardiographic monitoring and a variety of blood determinations. Site-specific complementary methods include physiologic and functional cardiovascular assessments of myocardial perfusion and metabolism, ventriculography, endothelial vascular function and coronary angiography. Women are followed for at least 1 year to assess clinical events and symptom status.